Table 2.
Adjusted hazard ratios (95 % CI) for incident T2DM, HTN, and CKD by age groups: Tehran lipid and glucose study.
| Age <60 years | Age ≥60 years | |||||||
|---|---|---|---|---|---|---|---|---|
| E/N | Model 1 | Model 2 | E/N | Model 1 | Model 2 | Interaction | ||
| HR (95 % CI) | HR (95 % CI) | HR (95 % CI) | HR (95 % CI) | p –value* | ||||
| Incident T2DM | ||||||||
| FPG <100 mg/dl | 380/4,400 | Reference | Reference | 110/877 | Reference | Reference | 0.037 | |
| FPG (100–125 mg/dl) | 91/151 | 7.51 (6.27–9.00) | 6.02 (5.00–7.26) | 30/65 | 4.35 (3.11–6.08) | 4.02 (2.87–5.62) | ||
| 2 h–PCG <140 mg/dl | 247/3,933 | Reference | Reference | 59/697 | Reference | Reference | 0.23 | |
| 2 h–PCG (140–199 mg/dl) | 224/618 | 7.07 (5.90–8.47) | 5.70 (4.73–6.87) | 81/245 | 4.89 (3.49–6.84) | 4.51 (3.22–6.32) | ||
| FPG <100 mg/dl or 2 h–PCG <140 mg/dl | 339/4,315 | Reference | Reference | 83/819 | Reference | Reference | 0.15 | |
| FPG (100–125 mg/dl) and 2 h–PCG (140–199 mg/dl) | 132/236 | 10.52 (8.60–12.89) | 7.95 (6.44–9.81) | 57/123 | 6.58 (4.70–9.23) | 5.96 (4.24–8.36) | ||
| Incident HTN | ||||||||
| FPG <100 mg/dl | 800/3,656 | Reference | Reference | 201/429 | Reference | Reference | 0.047 | |
| FPG (100–125 mg/dl) | 29/100 | 1.64 (1.37–1.95) | 1.38 (1.16–1.65) | 12/22 | 1.09 (0.80–1.50) | 0.96 (0.70–1.32) | ||
| 2 h–PCG <140 mg/dl | 685/3,337 | Reference | Reference | 173/357 | Reference | Reference | 0.001 | |
| 2 h–PCG (140–199 mg/dl) | 144/419 | 1.84 (1.54–2.20) | 1.51 (1.26–1.81) | 40/94 | 0.80 (0.56–1.12) | 0.76 (0.54–1.07) | ||
| FPG < 100 mg/dl or 2 h–PCG <140 mg/dl | 770/3,601 | Reference | Reference | 189/406 | Reference | Reference | 0.06 | |
| FPG (100–125 mg/dl) and 2 h–PCG (140–199 mg/dl) | 59/155 | 2.02 (1.55–2.64) | 1.62 (1.21–2.12) | 24/45 | 1.06 (0.69–1.63) | 1.00 (0.65–1.53) | ||
| Incident CKD | ||||||||
| FPG <100 mg/dl | 675/3,954 | Reference | Reference | 200/412 | Reference | Reference | 0.50 | |
| FPG (100–125 mg/dl) | 30/133 | 1.39 (1.15–1.69) | 1.13 (0.93–1.38) | 17/30 | 1.19 (0.88–1.60) | 1.00 (0.74–1.35) | ||
| 2 h–PCG <140 mg/dl | 588/3,543 | Reference | Reference | 161/328 | Reference | Reference | 0.33 | |
| 2 h–PCG (140–199 mg/dl) | 117/544 | 1.25 (0.73–1.33) | 0.97 (0.79–1.19) | 56/114 | 0.98 (0.73–1.33) | 0.81 (0.60–1.10) | ||
| FPG <100 mg/dl or 2 h–PCG <140 mg/dl | 659/3,880 | Reference | Reference | 187/387 | Reference | Reference | 0.65 | |
| FPG (100–125 mg/dl) and 2 h–PCG (140–199 mg/dl) | 46/207 | 1.34 (0.99–1.80) | 1.01 (0.74–1.36) | 30/55 | 1.06 (0.72–1.56) | 0.90 (0.61–1.33) | ||
FPG, fasting plasma glucose; 2 h–PCG, 2–h post–challenge plasma glucose; HR, hazard ratio; T2DM, type 2 diabetes mellitus; HTN, hypertension; CKD, chronic kidney disease.
Model 1, adjusted for age, and gender; model 2, adjusted for age, gender, body mass index, hypercholesterolemia, hypertension, current smoking, eGFR, prevalent CVD.
Bold values are statistically significant.